- Home
- CELC vs HZO Comparison
CELC vs HZO Comparison
Compare CELC & HZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HZO
- Stock Information
- Founded
- CELC 2011
- HZO 1998
- Country
- CELC United States
- HZO United States
- Employees
- CELC N/A
- HZO N/A
- Industry
- CELC Medical Specialities
- HZO Auto & Home Supply Stores
- Sector
- CELC Health Care
- HZO Consumer Discretionary
- Exchange
- CELC Nasdaq
- HZO Nasdaq
- Market Cap
- CELC 440.0M
- HZO 499.9M
- IPO Year
- CELC 2017
- HZO 1998
- Fundamental
- Price
- CELC $55.07
- HZO $26.17
- Analyst Decision
- CELC Strong Buy
- HZO Strong Buy
- Analyst Count
- CELC 5
- HZO 4
- Target Price
- CELC $53.60
- HZO $33.25
- AVG Volume (30 Days)
- CELC 862.3K
- HZO 270.3K
- Earning Date
- CELC 11-13-2025
- HZO 10-30-2025
- Dividend Yield
- CELC N/A
- HZO N/A
- EPS Growth
- CELC N/A
- HZO N/A
- EPS
- CELC N/A
- HZO N/A
- Revenue
- CELC N/A
- HZO $2,320,257,000.00
- Revenue This Year
- CELC N/A
- HZO N/A
- Revenue Next Year
- CELC N/A
- HZO $3.85
- P/E Ratio
- CELC N/A
- HZO N/A
- Revenue Growth
- CELC N/A
- HZO N/A
- 52 Week Low
- CELC $7.58
- HZO $16.85
- 52 Week High
- CELC $63.06
- HZO $37.86
- Technical
- Relative Strength Index (RSI)
- CELC 59.21
- HZO 52.06
- Support Level
- CELC $50.44
- HZO $24.71
- Resistance Level
- CELC $63.06
- HZO $26.84
- Average True Range (ATR)
- CELC 3.03
- HZO 1.01
- MACD
- CELC -0.90
- HZO -0.11
- Stochastic Oscillator
- CELC 44.24
- HZO 43.71
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HZO MarineMax Inc. (FL)
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.